Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Clinical trial NCT05058651 · SUSPENDED

Trial details

NCT number: NCT05058651
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Advanced Extrapulmonary Neuroendocrine Carcinoma Metastatic Extrapulmonary Neuroendocrine Carcinoma Recurrent Extrapulmonary Neuroendocrine Carcinoma Unresectable Extrapulmonary Neuroendocrine Carcinoma

Start date: 2022-06-28
Primary completion: 2028-10-01
Enrollment: 189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.